J. Indian Inst. Sci. | VOL 100:1 | 231-247 January 2020 | journal.iisc.ernet.in ammonia to afford a liquid with I 2 ···NH 3 interactions. 4 Five years later, in 1819, P. Pelletier and J. B. Caventou reported the synthesis of strychnine triiodide, where the triiodide anion (I 3 − ) is formed by the attractive interaction of iodine with iodide. 5 Based on the overwhelming subsequent reports on the formation of such chargetransfer interactions, in 2009, International Union of Pure and Applied Chemistry (IUPAC) started a project (project no. 2009-032-1-100) to take a comprehensive look at intermolecular interactions involving halogens as electrophilic species and classify them. 6 In 2013, these interactions received an IUPAC recommendation as halogen bonds. 7 Therefore, halogen bond (XB) is generally described as the noncovalent interaction, D···X-R, where X is an electrophilic halogen (XB donor), D is a donor of electron density (XB acceptor), and R is a carbon, nitrogen, or halogen atom (Fig. 1a) .
The electrophilic nature of halogens in organic halide originates from the anisotropic charge distribution. Many theoretical as well as experimental studies have shown that covalently bonded halogen atoms contain a significant amount of positive potential along the R-X ( Fig. 1a ) axis, and this region is called as σ-hole. 8, 9 Notably, as the polarizability increases down the group from F to I, the positive charge on σ-hole increases. As shown in Fig. 1b , the electrostatic potential remains negative around the fluorine atom in CH 3 F, while a region of positive potential emerges for chlorine, bromine, and iodine atoms in CH 3 Cl, CH 3 Br, and CH 3 I, respectively. 10 In contrast, electrostatic potential remains neutral all around methane (Fig. 1b ). Furthermore, σ-hole is surrounded by an electroneutral ring and further out, a negatively charged belt. Therefore, halogens can act as electrophile on approaching along the R-X axis (pole), whereas they behave as nucleophile on approaching perpendicular to the R-X axis (equator). As σ-hole is responsible for the formation of XBs, the strength of XB increases in the order F < Cl < Br < I and often times, this trend is used to characterize XBs. Notably, the strength of XBs can be enhanced by introducing electron-withdrawing groups on the carbon skeleton attached to the halogen atom. 11 Similarly, an increase in the electronegativity of the atom/moiety directly attached to halogen atom results in the formation of stronger XB, and therefore, XB strength order of C(sp)-X > C(sp2)-X > C(sp3)-X is generally followed. [12] [13] [14] The strength of XB is evaluated by the D···X interatomic distance-shorter the distance, stronger the interaction. Consistent with the electron donation from the XB acceptor to the antibonding orbital of the R-X bond, the formation of XB leads to a lengthening of the R-X bond. 15 XBs have extensively been used to form supramolecular architectures via self-assembly, to bind anions in solid and solution states, to catalyse organic transformations, to tune the photophysical emissive properties of organic chromophores, to resolve enantiomers, and to tailor the magnetic and conductive properties of Figure 1 : a Schematic representation of halogen bond. b Ab initio electrostatic potential surfaces of halogenated methanes (X-Me) and methane (last column), indicating the negative (red), neutral (green), and positive (blue) electrostatic potentials around the halogen surfaces. Reproduced from reference 10 with permission. 10 molecular materials, and all these aspects have been discussed in several excellent reviews. [16] [17] [18] [19] Halogen bonding has also been found in several protein-ligand complexes as well as nucleic acids containing halogenated nucleotides. 10, [20] [21] [22] [23] [24] [25] Notably, incorporation of halogen has been a useful tool in medicinal chemistry to increase the potency and selectivity of bioactive small molecules to a target protein. [23] [24] [25] [26] Additionally, Mugesh and coworkers have recently shown that incorporation of halogens in small molecule fluorophores as well as fluorescent proteins, such as green fluorescent protein (GFP), dramatically enhances their cellular uptake, possibly due to the formation of XBs with cell surface receptors. [27] [28] [29] In protein-ligand complexes, XBs are formed between the halogenated ligand and a properly oriented electron donor (Lewis base) in the binding pocket. Backbone carbonyl functionality (C=O) in the amino acids has been found to be the most frequent Lewis base involved in the formation of XBs in protein-ligand complexes. However, the side chain functionalities, such as hydroxyls in Ser, Thr and Tyr, sulphurs in Cys and Met, carboxylates in Asp and Glu, imidazole nitrogens in His, and the aromatic π-systems in Phe, Tyr, Trp, and His can also form XBs. 10, 24, 25, 30 In this minireview, we focus on the role of XBs in the molecular recognition of thyroid hormones (THs) and their metabolites, which are probably the best known examples of naturally occurring iodinated molecules that bind to various transport proteins and thyroid hormone receptors.
Thyroid Hormones and Their Action
Thyroid hormones are key players of human endocrine system and they control almost every processes in the body, including brain development, growth, carbohydrate and fat metabolism, protein synthesis, and cardiovascular and renal functions. Thyroid hormones are biosynthesized in the follicular lumen of the thyroid gland, and their secretion is controlled by the hypothalamus and pituitary gland in brain. [31] [32] [33] [34] With help of iodide (imported by sodium iodide symporter) and hydrogen peroxide (generated by dual oxidases), thyroid peroxidase (TPO) iodinates tyrosine residues in thyroglobulin (Tg), a tyrosine-rich glycoprotein on which thyroxine biosynthesis takes place, and this process is known as organification of inorganic iodide. Phenolic coupling of two diiodotyrosine residues on Tg (catalysed by thyroid peroxidase) and subsequent proteolysis release the prohormone, 3,5,3′,5′-tetraiodothyronine (thyroxine or T4) into blood stream ( Fig. 2, 3a ). 35 T4 is then carried into various target organs by three transport proteins in serum-thyroxinebinding globulin (TBG), transthyretin (TTR), and serum albumin (HSA, for human). 36 In the target organs, the prohormone is then converted to the biologically active metabolite, 3,5,3′-triiodothyronine (T3, Fig. 3a ) by regioselective phenolic ring (5′) deiodination, catalysed by mammalian selenoenzymes, and iodothyronine deiodinase type 1 (DIO1) and type 2 (DIO2). [37] [38] [39] [40] Subsequently, T3 binds to the nuclear thyroid hormone receptors (TRs) Figure 2 : Schematic representation of secretion, transport, and action of thyroid hormones, T4 and T3 in the target organs. TP: transport protein, DIO: iodothyronine deiodinase, TR: thyroid hormone receptor, TRE: thyroid hormone responsive element, RXR: retinoid X receptor. that exist as homodimer or heterodimer with the 9-cis-retinoic acid receptor (RXR). The binding of TR/RXR complex to the thyroid hormone responsive elements (TREs, a specific nucleotide sequence) on the target genes facilitates the activation of co-repressor and coactivator proteins that ultimately regulate gene expression ( Fig. 2 ). 41, 42 Interestingly, both T4 and T3 form XBs with the transport proteins as well as nuclear receptors, and these interactions play important roles in the molecular recognition process. Furthermore, several biochemical and biomimetic studies suggest that the selenocysteine in the active site of DIOs form XB with THs to polarize the C-I bond for reductive deiodination. In the following sections, we discuss the XBs formed by THs and their metabolites with transport proteins and nuclear thyroid hormone receptors.
Thyroid Hormone Transport Proteins
Owing to high hydrophobicity, THs cannot circulate in the blood in the free (unbound) state. As soon as they enter the blood stream from the thyroid gland, three transport proteins, TBG, TTR, and HSA bind them, and carry to various target organs. 35, 36 Although TBG exhibits the highest affinity for THs amongst the three proteins, higher plasma concentrations of TTR (4.6 µM) and HSA (640 µM) compared to TBG (0.27 µM) make TTR and HSA as high-capacity TH carrier. 36 Owing to low affinity, the binding of THs to TTR and HSA exhibits fast dissociation kinetics. Notably, the dissociation of T4 from the ligand-binding sites facilitates the unfolding of TTR, leading to the formation of toxic amyloid aggregates and their deposition in various organs. 43 Almost 74% of total T4 is carried by TBG, while only 11% and 15% of the same remain bound to TTR and HSA, respectively. However, TTR is the only TH-binding protein in the cerebrospinal fluid (CSF). 35 Binding of THs to serum transport proteins also ensure the slow clearance and prolonged half-life in blood serum.
Transthyretin (TTR)
Although TBG is the major TH carrier in serum in humans, in rat and other lower vertebrates, TTR is the primary TH carrier. TTR (also known as prealbumin) is mainly synthesized in liver. TTR also transports Vitamin A by forming a stable complex with retinol-binding protein (RBP) Figure 3 : a Chemical structures of T4, T3, and 3,3′-T2. b X-ray crystal structure of human transthyretin (TTR) bound to T4, indicating the hydrogen and halogen-bonding interactions responsible for T4-binding (PDB code: 2ROX). 44 X-ray crystal structure of sea bream (C), (PDB code: 1SN5) 45 and human (D), (PDB code: 1THA) 46 TTR in complex with T3 and 3,3′-T2, respectively, indicating the interactions responsible for molecular recognition.
at the outer surface. 35, 36 Although TTR exhibits the highest affinity (100%) for binding T4, it can also bind various TH metabolites with lower iodine content, such as T3, 3,3′-T2 and 3-T1 ( Fig. 3a ). However, the affinity of TTR for these metabolites is remarkably lower (0.07% for 3,3′-T2, < 0.01% for 3-T1) than that observed for T4, indicating that the number of iodine atoms also plays an important role in the binding. 35, 36 TTR exhibits a homotetrameric quaternary structure with a molecular weight of 55 kDa and this structure results from the assembly of four identical 127 residue polypeptide chains or monomers (A, B, C, and D) around a central channel ( Fig. 3b ). 44 Each monomer unit has a β-barrel structure consisting of eight strands (A-H) and a short α-helix after F strand. Although TTR contains two sterically equivalent T4-binding sites (Site I and II) at the weak dimer-dimer interface (Fig. 3b ), these sites exhibit different binding affinity for T4. Site I (between monomer A and C) exhibits 100times higher affinity for T4 than site II (between monomer B and D) (dissociation constant (K d ), 10 −8 M for site I and 10 −6 M for site II) and a negative cooperative effect for the binding of T4 to TTR is proposed. 35, 36 The crystal structure of human TTR-T4 complex (orthorhombic form, PDB code: 2ROX) indicates that in both site I and II, the 4′-OH group of T4 points towards the centre of the channel, while the β-alanine side chain protrudes towards the solvent-exposed surface. This binding orientation is called as the forward mode, while the opposite orientation with 4′-OH group towards the surface and β-alanine side chain towards the central channel is called as reverse mode. In the forward mode, 4′-OH group is stabilized by hydrogen bonding with S117, while the β-alanine side chain forms salt-bridge interactions with K15 and E54 residues ( Fig. 3b ). 44 TTR also contains three pairs of symmetry-related halogen-binding pockets (HBPs), HBP1(HBP1′), HBP2(HBP2′), HBP3(HBP3′) comprising the hydrophobic side chains and nucleophilic backbone carbonyl groups. For example, HBP3 is formed by backbone and side chains of A108, A109, L110, T188, T119, and S11. Interestingly, in site I, the 3-and 5-iodine atoms are accommodated in HBP1 and HBP1′ pockets through hydrophobic interactions, while the 3′-iodine in HBP3′ forms a strong I···O XB with the backbone carbonyl of A109 ( Fig. 3b , see left panel). This XB is characterized by an I···O distance (d) of 2.8 Å, which is 20% shorter than the sum of van der Waal′s radii of oxygen and iodine (3.5 Å). 44 Furthermore, Θ 1 (∠C T4 IO) and Θ 2 (∠IOC A109 ), as shown in Table 1 , are 162.0° and 94.1°, respectively, which are in agreement with the proposed ideal geometry (Θ 1 ~ 180° and Θ 2 ~ 90°) for effective formation of XB. 16, 18, 19 3′-Iodine also forms a weak XB with the backbone NH of A109 with I···N distance of 3.5 Å (0.8% shorter than the sum of van der Waal′s radii of iodine and nitrogen, 3.53 Å), and Θ 1 and Θ 2 of 134.7° and 93.5°, respectively ( Fig. 3b and Table 1 ). Although Θ 1 for this interaction is deviated from the ideal geometry, significant numbers of XBs with Θ 1 between 130° and 150° are known in several protein-ligand complexes. 10, 24 5′-Iodine atom also form a weak I···N XB with the backbone NH of L110′. Generally, the amidic nitrogen atom forms weak halogen bond due to the conjugation of the lone pair of nitrogen atom with the carbonyl group. This XB is characterized by d I···N , Θ 1 , and Θ 2 of 3.5 Å, 134.1°, and 100.9°, respectively. In contrast to site I, only one I···O XB (d I···O : 3.3 Å, Θ 1 : 166.8°, Θ 2 : 90.4°) is observed between the 3′-iodine and backbone carbonyl of A109 in site II (Fig. 3b , see right panel and Table 1 ). 44 Notably, this I···O XB is weaker than that observed in site I. These observations indicate that the formation of weaker XB as well as fewer interactions may account for the 100-fold lower affinity of site II for T4 than site I.
The monoclinic form of human TTR in complex with T4 (PDB code: 1ICT) indicates extensive formation of XBs in both the sites involving the 3′-and 5′-iodine of T4. 47 In contrast to the orthorhombic form, 3′-iodine forms three moderately strong XBs with the backbone carbonyl of A108, and backbone NH of A109 and L110 residues ( Table 1 ). The 5′-iodine forms two XBs with the backbone carbonyl and side chain hydroxyl group of S117′ residue, although the XB formed with backbone carbonyl (d I···O : 3.3 Å) is little stronger than with the side chain hydroxyl (d I···O : 3.4 Å). In site II, T4 moves 1.5 Å deeper towards the central channel compared to Site I, thereby placing the 3′-and 5′-iodine atoms in HBP3 and HBP3′ pockets. In site II, 3′-iodine forms only one XB with the backbone NH of T119 with a I···N distance of 3.3 Å (6.5% shorter than the sum of van der Waal′s radii) ( Table 1 ). Similar to site I, the other phenolic iodine atom (5′) interacts with the backbone carbonyl and side chain hydroxyl group of S117′, although, in contrast to site I, both these interactions are of equal strength (d I···O : 3.2 Å, 8.6% shorter than the sum of van der Waal′s radii). Additionally, 5′-iodine also forms a I···N XB with the backbone NH of T119′ (d I···N : 3.4 Å, Θ 1 : 115.1°, Θ 2 : 107.2°). 47 J. Indian Inst. Sci. | VOL 100:1 | 231-247 January 2020 | journal.iisc.ernet.in Another X-ray crystal structure of human TTR in complex with T4 (PDB code: 1ETA) at 1.7 Å resolution was solved by Hamilton et al. 48 In contrast to the orthorhombic form described earlier, this structure (also in the orthorhombic form) shows that in both the sites, 3′-iodine of T4 forms an equally strong I···O XB (d I···O : 3.1 Å) with the backbone carbonyl of A109 (Table 1) . 48 Authors have also solved the structure of an A109T variant of TTR, associated with euthyroid hyperthyroxinemia, in complex with T4 (PDB code: 1ETB). 49 Interestingly, this variant also forms I···O XBs with its T109 residue in both the sites. However, these XBs were found to be weaker (d I···O : 3.3 Å in site I and 3.2 Å in site II, Table 1 ) than that observed in case of wildtype protein.
Rat TTR-T4 complex crystallizes in the tetragonal form (PDB code: 1IE4) and this crystal structure exhibits that in addition to hydrogen bonding and ion pair interactions in site I, the 3′-iodine forms a moderately strong I···O XB (d I···O : 3.1 Å, Θ 1 : 158.2°, Θ 2 : 100.9°) with A109 residue. 50 In contrast, in site II, 3′-iodine forms both I···O and I···N XBs with the backbone carbonyl and NH groups of A109, respectively, while 5′-iodine forms only I···N (with A109′) XB (Table 1) . However, these XBs are found to be much weaker than that observed in site I. 50 In contrast to rat and human TTR, sea bream TTR in site I does not form any I···O XB with the 3′-iodine of T4. 45 However, a weak I···N XB (d I···N : 3.5 Å, Θ 1 : 131.7°, Θ 2 : 109.7°, Table 1) is formed by backbone NH of L109 with the 3′-iodine of T4. In this site, a weak I···O interaction is also formed by the 5′-iodine of T4 with the backbone carbonyl of L109′ residue. As shown in Table 1 , relatively stronger XB interactions are formed in site II by both the 3′-and 5′-iodine atoms of T4 with L109 and L109′ residues. 45 These observations indicate that human TTR forms much stronger XBs with T4 than rat or sea bream TTR, and it appears that TTR has evolved in higher vertebrates to bind T4 more efficiently.
TTR is also known to bind various metabolites of T4 and several crystal structures of TTR in complex with T4 metabolites have been reported in literature. Crystal structure of sea bream TTR-T3 complex (PDB code: 1SN5) reveals different binding modes for T4 and T3. 45 Interestingly, sea bream TTR exhibits higher affinity for T3 than T4, whereas human and rat TTR exhibit higher affinity for T4 than T3. The 3-and 5-iodine atoms of both T3 and T4 occupy the same halogen-binding pockets (HBP1and HBP1′), while the 3′-iodine atom of T3 occupies a place of that is occupied by the 4′-hydroxyl group of T4. In site I, three different binding modes for T3 were observed on the basis of electron density maps of 4′-hydroxyl group and 3′-iodine atom (Fig. 3c ). In one of these modes, 3′-iodine forms a strong I···O (d I···O : 3.0 Å, Θ 1 : 172.6°, Θ 2 : 96.4°) and a moderate I···N (d I···N : 3.4 Å, Θ 1 : 129.3°, Θ 2 : 106.2°) XB with the backbone of L109 (Table 1) . 45 Whereas in site II, none of these XBs are observed, indicating that site I may have higher affinity to T3 like T4. The formation of strong I···O XB with T3 may also explain the higher affinity of sea bream TTR for T3 than T4. The crystal structure of human TTR in complex with 3,3′-T2 (PDB code: 1THA) reveals that due to more flexible character, 3,3′-T2 moves 3.5 Å deeper (compared to T4) into the central channel and exhibits a twisted conformation of the phenolic and tyrosyl rings. 46 In contrast, T4 binds to human TTR in skewed conformation. 3′-iodine of 3,3′-T2 also forms I···O XBs with the backbone carbonyl and side chain hydroxyl groups of S117, although the XB formed with side chain hydroxyl (d I···O : 2.9 Å, Θ 1 : 102.5°, Θ 2 : 128.7°) is much stronger than with the backbone carbonyl (d I···O : 3.2 Å, Θ 1 : 144.8°, Θ 2 : 84.2°). Similar type of interaction is also present in site I; however, only backbone carbonyl of S117 interacts with the 3′-iodine of 3,3′-T2. 46 In addition to deiodination, THs undergoes a number of metabolic pathways, such as sulphate conjugation, glucoronidation, decarboxylation, and oxidative deamination that lead to the formation of iodothyronine sulphate, glucoronidated iodothyronine, iodothyroamine, and iodothyroacetic acid, respectively. 35, 51 It is known that iodothyroacetic acid can bind to thyroid hormone receptors (discussed later) and exhibits thyromimetic activity by suppressing TSH levels. 52 3,5,3′,5′-tetraiodothyroacetic acid (TA4 or tetrac) and 3,5,3′-triiodothyroacetic acid (TA3 or triac) are biosynthesized from T4 and T3, respectively. T4 undergoes oxidative deamination by transaminase to form 3,5,3′,5′-tetraiodothyropyruvic acid followed by decarboxylation by L-amino acid oxidase (LAO) to form TA4 (Fig. 4a ). 35, 51, 53 TA4 has been shown to be a substrate of iodothyronine deiodinase type I (DIO1) that catalyses the regioselective 5′-deiodination of TA4 to produce TA3 (Fig. 4a ). 35, 51, 54, 55 Interestingly, TA4 exhibits 2.8-fold higher affinity to human TTR than T4. In contrast to T4, TA4 can bind TTR both in the forward mode and reverse mode. However, the population of reverse binding mode is more in both the binding sites. The preferable binding in reverse mode may arise due to the small side chain that can penetrate more through the narrow central channel of TTR. Crystal structure of human TTR-TA4 complex (PDB code: 1Z7J) reveals that in the forward mode, the 3′-and 5′-iodine atoms occupy the HBP3 and HBP2′ pockets in both the binding sites. 56 While 4′-OH group does not form hydrogen bond with S117, the carboxylate side chain forms salt-bridge interaction with K15. In the reverse binding mode, 4′-OH group forms hydrogen bond with K15 and the carboxylate side chain occupies the HBP3 pocket. In this mode, the 3-and 5-iodine atoms occupy the HBP1(1′) pockets, whereas the 3′-and 5′-iodine atoms occupy HBP2(2′) pockets. In both the sites, XB interactions are formed by the 3′-iodine specifically in the forward binding mode (Fig. 4b) .
For example, 3′-iodine forms a strong I···O XB with the backbone carbonyl of A109 (in site I) and A309 (in site II), although the XB in site I (d I···O : 2.8 Å, 20% shorter than the sum of van der Waal′s radii) is stronger than in site II (d I···O : 3 Å, 14.3% shorter than the sum of van der Waal′s radii) ( Table 1) . 56 In both the sites, the 3′-iodine also forms I···N XB with the backbone NH of A109 (in site I) and L310 (in site II), and in contrast to I···O XBs, these interactions are of equal strength. Rat TTR also binds TA4 both in the forward and reverse binding mode in site I, whereas in site II, only forward mode is observed (PDB code: 1KGI). 57 Similar to human TTR-T4 (monoclinic form) and rat TTR-T4 complexes, 3′-and 5′-iodine atoms in TA4 occupy the HBP3(3′) pockets in the forward mode. Two electron densities for TA4 are found in site II and 3′-iodine in both the molecules form two almost identical I···O XBs with the backbone carbonyls of A309 and A709 residues ( Fig. 4c and Table 1 ). Backbone NH of A709 also forms an I···N XB with the 3′-iodine of one of the molecules. 57 Comparisons of the strength of these XBs with those observed in human TTR-TA4 complex indicate that human TTR may exhibit higher affinity to TA4 than rat TTR.
Human Serum Albumin (HSA)
Human Serum Albumin (HSA) is the most abundant protein in human plasma with a molecular weight of 66,437 Da. HSA is mainly responsible for the transport of non-esterified fatty acids, bilirubin, bile acids, steroid, and thyroid hormones. Amongst all three transport proteins, HSA exhibits lowest affinity to T4 (K d ~ 2 µm). 35, 36 Monomeric HSA contains three homologous domains (I, II and III) and each of these domains contains two subdomains (A and B). Crystal structure of HSA in complex with T4 (PDB code: 1HK1) indicates that there are four T4-binding sites (Tr1, Tr2, Tr3 and Tr4) in HSA (Fig. 5a ). 58 While Tr1 and Tr2 is located in the subdomains IIA and IIIA, respectively, both Tr3 and Tr4 are located in the IIIB subdomain. Among these four sites, Tr1 exhibits the highest affinity to T4, which exhibits a less stable cisoid (the phenolic ring and β-alanine side chain remain in the same faces of the tyrosyl ring) conformation at Tr1, whereas it exhibits the common transoid (the phenolic ring and β-alanine side chain remain in the opposite faces of the tyrosyl ring) conformation in the other binding sites. 59, 60 This is mainly because of the presence of large hydrophobic side chains of F223, R222, R218, and W214 in Tr1, and these residues push the β-alanine side chain of T4 to the other side of the tyrosyl ring (Fig. 5b) . Mainly hydrophobic interactions are responsible for the bonding of T4 to Tr1, although a few hydrogen bonds, such as between 4′-OH group and R257 as well as Y150, carboxylate functionality, and K199 are also observed. The 3-iodine of T4 forms a I···O XB (d I···O : 3.2 Å, Θ 1 : 146.6°, Θ 2 : 126.7°) with the backbone carbonyl of I290 ( Fig. 5b and Table 2 ). 58 Notably, unlike in TTR, the 3′-and 5′-iodine atoms do not form any XBs with HSA. As R218 sterically hinders the β-alanine side chain of T4 in Tr1, mutation of this residue to either His or Pro increases the binding affinity by making more room for the β-alanine side chain of T4. The relaxation of the β-alanine side chain leads to the formation of weaker XB with I290 in the R218H (d I···O : 3.3 Å, PDB code 1HK2) and R218P (d I···O : 3.4 Å, PDB code 1HK3) mutants (Table 2 ). However, decrease in XB strength does not lead to a decrease in affinity; rather, R218H and R218P mutants exhibit 10-15-fold higher affinity for T4. 58 Probably, the other hydrophobic and hydrogen-bonding interactions compensate for the weaker XB.
While in other binding sites (Tr2, Tr3, and Tr4), T4 forms predominantly hydrophobic interactions, two hydrogen-bonding interactions involving the 4′-hydroxyl group of T4 and Y411 and S489 residues are observed in Tr2 (Fig. 5c ). Furthermore, in Tr2, the 3-and 5-iodine atoms of T4 make I···O interactions with the backbone carbonyl of A406 (d I···O : 3.5 Å) and L387 (d I···O : 3.5 Å) residues, respectively ( Fig. 5c and Table 2 ). While the I···O contact with A406 in the wild-type protein is just equal to the sum of van der Waal′s radii of iodine and oxygen, it is found to be stronger in R218H mutant (d I···O : 3.3 Å, Table 2 ). 58 However, in the R218P mutant, both these interactions with A406 and L387 are really weak (d I···O : 3.5 Å). Similarly, in Tr3, the 5-iodine atom forms a weak interaction with backbone carbonyl of K524 of the wild-type protein with I···O distance of 3.5 Å (Fig. 5d ). These interactions are much stronger in the R218H (d I···O : 3.2 Å) and R218P (d I···O : 3.1 Å) mutants ( Table 2 ). In Tr4 of wild-type HSA and R218H mutant, the 5′-iodine of T4 forms I···S XB with the side chain of M548 residue ( Fig. 5e and Table 2 ). These interactions have d I···S of 3.6 Å that is 7.4% shorter than the sum of van der Waals radii of sulphur and iodine (3.78 Å). Also, these interactions have nearly identical Θ 1 and Θ 2 . 58 However, this I···S XB is absent in the R218P mutant. Altogether, Tr1 forms maximum number of interactions (both hydrogen bonding and XB) and the strongest XB with T4, and these lead to the higher affinity of Tr1 to T4. Interestingly, a new T4-binding site (Tr5) is found between the domains I and III of HSA-myristate complex that binds only one equivalent of T4. In this site, both 4′-hydroxyl group and β-alanine side chain of T4 are solvent exposed, and the other parts of T4 are stabilized by hydrophobic interactions. One prominent I···O XB is formed between the backbone carbonyl of N429 and 3-iodine atom of T4 with d I···O of 3.2 Å (Table 2) . However, in R218H mutant, this interaction is not prominent (d I···O : 3.5 Å). 58
Thyroxine-binding globulin (TBG)
Thyroxine-binding globulin (TBG), the principal thyroxine carrier in serum, is a member of serine protease inhibitor (SERPIN) family. It has the highest affinity to T4 with a K d value of 0.1 nM. 35, 36 TBG contains two identical sites for T4 in a surface cavity between helices H and A, and strands 3-5 of the β-sheet (Fig. 6a ). 61 T4 at these sites mainly forms a series of hydrophobic interactions. Also the β-alanine side chain forms hydrogen-bonding interactions with N273 and R378 residues (Fig. 6b ). Furthermore, 3-iodine of T4 forms a weak I···O interaction (d I···O : 3.5 Å, Θ 1 : 131.6°, Θ 2 : 119.2°) with the backbone carbonyl of L269. 61 Unlike other transporter proteins, T4 release from TBG is controlled by an allosteric mechanism. 61, 62 Similar to other protease inhibitors in SERPIN family, TBG contains a reactive centre loop (RCL), and the cleavage of this loop leads to an irreversible change in the conformation of TBG. This conformational change leads to an almost threefold decrease in the affinity to T4. The crystal structure of human TBG with cleaved RCL in complex with T4 reveals that the β-alanine side chain of T4 forms the hydrogen-bonding interactions with N273 and R378 residues, similar to the uncleaved protein ( Fig. 6b , c, PDB code: 2RIW). 62 It is observed that the 3-iodine atom forms a stronger I···O XB Figure 6 : a Crystal structure of TBG in complex with T4, indicating the T4-binding sites (PDB code: 2CEO). 61 Hydrogen bonding and XB interactions between T4 and TBG observed in human TBG (b, PDB code: 2CEO) and human TBG without the reactive centre loop (c, PDB code: 2RIW). 61, 62 d Hydrogen bonding and XB interactions observed in the cocrystal of human TBG and T4-fluorescein conjugate (PDB code: 2XN6). 62 Fluorescein part is not shown for clarity.
with L269 residue than the uncleaved protein.
This XB has d I···O of 3.3 Å, and Θ 1 and Θ 2 are almost similar to that observed in the uncleaved protein complex (Fig. 6b, c) . Human TBG has also been crystallized with a T4-fluorescein conjugate and this conjugate forms the strongest I···O XB among the three described above (d I···O : 3.2 Å, Θ 1 : 128.1°, Θ 2 : 125.6°) with the backbone carbonyl of L269 residue (Fig. 6d ). 62 These results indicate that in addition to hydrogen bonding and hydrophobic interactions, XB also play an important role in the molecular recognition of T4 by TBG. 
Thyroid hormone receptors (TRs)
Thyroid hormone receptors (TRs) are members of nuclear receptors superfamily that regulate gene transcription and translation upon binding to the biologically active TH, T3. The binding of T3 induces a conformational change of the receptor that helps in binding the co-regulator proteins. Furthermore, TRs bind the promoter region of the target gene by recognizing specific nucleotide sequences, called as thyroid hormone response elements (TREs). 42, 63, 64 There are two genes of TRs (THRA and THRB) and differential splicing of these genes lead to the production of four different receptor isoforms designated as TRα1, TRα2, TRβ1, and TRβ2. Expression of these isoforms are tissue-specific-TRα1 has highest expression in heart and skeletal muscle; TRβ1 is expressed in liver, kidney, and brain; TRβ2 is expressed in anterior pituitary and hypothalamus. While TRα1 is involved in the maintenance of cardiovascular functions, TRβ1 is mainly associated with metabolism of cholesterol and lipoproteins. 42, 65, 66 Similar to other nuclear receptors, TRs also have four domains-N terminal A/B domain (NTD), DNA-binding domain (DBD), C-terminal ligand-binding domain (LBD), and a small hinge between LBD and DBD. 42 The ligand-binding pocket of both subtypes of TRs differs only by a single amino acid residue (S277 in TRα and N331 in TRβ). 35, 52 Both the receptor subtypes have almost 30-fold higher affinity for T3 (K d = 0.06 nM) over T4 (K d = 2 nM). The X-ray crystal structure of TRα1 in complex with T3 (monoclinic form, PDB code: 2H77) reveals that T3 binds inside a hydrophobic core of LBD, and the ligand-binding pocket is made up with several residues from helix 5-6 (H5-6, Met256-Arg266), helix 7-8 (H7-8), and the intervening loop (Leu287-Ile 299), helix3 (H3, Phe215-Arg228), helix 11 (H11, His381-His387), and helix 12 (H12, Phe401-Phe405). 67 TRα1-bound T3 exhibits the more stable transoid conformation and forms mainly hydrophobic interactions, although the carboxylate group is involved in hydrogen bonding with R228 ( Fig. 7a ). Interestingly, the 3-iodine atom forms a I···O XB with backbone carbonyl of F218 with d I···O of 3.1 Å, which is 11.4% than the sum of the van der Waal′s radii of oxygen and iodine. The Θ 1 (174.4°) and Θ 2 (113.6°) of this XB also match the ideal geometry proposed for XB formation (Table 3) . Similar XB is also found in the orthorhombic form of TRα1 in complex with T3 (Table 3 , PDB code: 2H79). 67 Recently Souza et al. have shown that T3 can bind to a separate site located between helix H9, H10, and H11 on the surface of TRα1. 68 This binding affinity at this new site is of the order of plasma or intracellular concentration of T3 and T4, indicating that THs can bind to this under physiological conditions. Crystal structure of TRα1 bound to T3 at this new (noncanonical) site (PDB code: 4LNW) reveals that T3 exhibits cisoid conformation unlike in the canonical site in LBD. T3 binds to this site mainly by hydrogenbonding interactions with Q342, S326 and R375 residues (Fig. 7b ). Furthermore, the backbone carbonyl of L368 forms an XB interaction with the 3-iodine of T3 with d I···O : 3.2 Å, Θ 1 : 154.8°, and Θ 2 : 121.5° (Table 3) . 68 T4 can also bind to this site, and exhibits similar conformation and interactions with TRα1 (PDB code: 4LNX).
Notably, similar to T3, the 3-iodine of T4 also forms an I···O XB with L368 (Table 3) . 68 The crystal structure of TRβ in complex with T3 (PDB code: 1XZX) indicates that T3 exhibit similar binding interactions as observed in the TRα1-T3 complex. 69 While the carboxylate group of T3 interacts with S277 in TRα1, it forms hydrogen bond with R282 and N331 in TRβ (Fig. 7c ). Furthermore, unlike in TRα1, the 4′-hydroxyl group forms hydrogen bond with H435 in TRβ. In the hydrophobic core, the 3-iodine of T3 forms XB with backbone carbonyl of F272 with d I···O of 3.2 Å, which is 8.6% shorter than the sum of van der Waal′s radii of iodine and oxygen ( Table 3 ). The Θ 1 (165.9°) and Θ 2 (121.8°) of this XB are very similar to those observed in the TRα1-T3 complex ( Table 3 ). 69 T4 exhibits lower affinity than T3 due to the presence of two bulky phenolic ring iodine atoms that create strong steric hindrance in ligandbinding pocket. The crystal structure of TRβ in complex with T4 (PDB code: 1Y0X) reveals that T4 binding leads to an expansion of the ligandbinding pocket to accommodate the bulky 5′-iodine. Like T3, the 3-iodine atom of T4 forms a XB with backbone carbonyl of F272 with d I···O : 3.2 Å, Θ 1 : 167.6°, and Θ 2 : 119.7°. 69 Although T4 forms identical interactions with TRβ as T3, the lower affinity of T4 may result from the deformation of the ligand-binding pocket to accommodate the bulky 5′-iodine.
As mentioned earlier, 3,5,3′-triiodothyroacetic acid (TA3) exhibits thyromimetic activity by binding to TRs. 35, 52 Interestingly, TA3 is found to be threefold more selective to TRβ than TRα, indicating that triac can be used for treating thyroid hormone resistance syndrome (RTH) that results from the mutations in TRβ1 gene. Comparison of the crystal structures of TRα-TA3 (PDB code: 3JZB) and TRβ-TA3 (PDB code: 3JZC) complexes reveal that TA3 forms hydrogen bond with R266 in TRα, whereas it forms hydrogen bonds with H435, N331, and R320 in TRβ (Figs. 7e, f) . 70 In the hydrophobic core, the 3-iodine of TA3 makes moderately strong I···O XBs with F218 (in TRα) and F272 (in TRβ). Both of these XBs are found to be of equal strength and to have almost identical Θ 1 and Θ 2 ( Table 3 ). The TRβ selectivity of TA3 is explained on the basis of higher volume of ligand-bonding pocket (500 Å 3 in TRβ versus 461 Å 3 in TRα) in TRβ that allows more solvation and flexibility of the acetic acid side chain of TA3. 70 
Conclusions
In this minireview, we have discussed the molecular interactions that are responsible for the binding of thyroid hormones and their metabolites with various serum transport proteins and thyroid hormone receptors with a special emphasis on the halogen bonds (XBs). All the serum transport proteins for thyroxine form XBs with T4 as well as the deiodinated metabolites, T3. While transthyretin extensively forms XBs with the phenolic ring iodine atoms of T4 and T3, thyroxine-binding globulin forms XB only with tyrosyl ring iodine of T4. However, human serum albumin can form XBs with both phenolic and tyrosyl ring iodine in different binding sites. Furthermore, in addition to hydrogen bonding, XBs also play important roles in the binding of T4 and T3 to the thyroid hormone receptors (TRs), TRα and TRβ. Similar to TBG, TRs also form XBs with only tyrosyl ring iodine. Triiodothyroacetic acid, an endogenous TH metabolite, that exhibits thyromimetic activity also forms XBs with TRs. Although the backbone carbonyl and amide groups are predominant, side chain hydroxyl of Ser, and sulphur atom of Met also function as XB acceptors in a few XBs. The presence of such interactions with thyroxine and its metabolites indicates that the biological systems use iodine atoms as part of the thyroid hormones to provide higher selectivity of these key hormones to the transport proteins and receptors.
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